Evidence map›Paper›PMID 40066078›Full record

ReviewMaterials today. Bio2025

Recent advances and future directions in urinary system tissue engineering.

Jie Yuan, Di Suo, Penghui Li, Xin Zhao, Huaiyu Wang, Binghai Chen

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jie YuanDepartment of Urology, Affiliated Hospital of Jiangsu University, 438 North Jiefang Road, Zhenjiang, Jiangsu, 212001, PR China.
Di SuoDepartment of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, PR China.
Penghui LiInstitute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, PR China.
Xin ZhaoDepartment of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, PR China.
Huaiyu WangInstitute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518055, PR China.
Binghai ChenDepartment of Urology, Affiliated Hospital of Jiangsu University, 438 North Jiefang Road, Zhenjiang, Jiangsu, 212001, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advancements in tissue engineering offer promising solutions for the repair and reconstruction of the urinary system, particularly in cases of urinary organ injuries. Historically, autologous tissue grafts and allografts have been the primary options for repairing damaged tissues. However, these approaches often lead to complications such as immune rejection, donor site morbidity, and functional limitations. Tissue engineering provides a more sustainable alternative by leveraging the potential of cells, bioactive scaffolds, and growth factors to regenerate and repair damaged tissues. This approach aims not only to restore tissue structure but also to enhance functional recovery. Key challenges in the field include achieving adequate vascularization, overcoming immune responses, and ensuring long-term tissue integration. Recent innovations, such as 3D bioprinting, stem cell-based therapies, and the development of novel biomaterials, show great promise in addressing these challenges. This review explores the current state of tissue engineering applications in the urological system, focusing on the regeneration of the bladder, urethra, and kidneys. We discuss recent breakthroughs, ongoing clinical trials, and emerging technologies, as well as the potential for these approaches to improve clinical outcomes. Finally, we outline critical future directions of tissue engineering in urology, emphasizing the need for interdisciplinary collaboration to overcome existing barriers and accelerate clinical translation.

Indexed as

AntibacterialAnti-inflammatoryAntitumorTissue regenerationUrinary systemVascularization

Identifiers

PMID40066078
PMCPMC11891153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.